Division of Viral Hepatitis, CDC

Slides:



Advertisements
Similar presentations
Adherence to HCV Therapy: Relation with Virologic Outcomes and Changes in Adherence Over Time Vincent Lo Re, MD, MSCE V. Teal, R. Localio, V. Amorosa,
Advertisements

The effect of improved HCV diagnosis and treatment on public health The effect of improved HCV diagnosis and treatment on public health P Mathurin Hôpital.
Edited by Morris Sherman MD BCh PhD FRCP(C) Associate Professor of Medicine University of Toronto Protease Inhibitors in Chronic Hepatitis C: An Update.
Liver Disease and Thalassaemia George Constantinou.
Role of Health Information Technology in Nationwide Outbreaks Chesley Richards, MD, MPH Director, Office of Public Health Scientific Services Centers for.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a versus Interferon alfa-2a Phase 3 Treatment Naïve, Chronic HCV Zeuzem S, et al. N Engl J.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin versus Interferon alfa-2b + Ribavirin Phase 3 Treatment Naïve, Chronic HCV Manns.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIAID SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.
Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.
Assessment of Program Evaluation Activities in Tuberculosis Control Programs — United States, 2009–2010 Silvia M. Trigoso, MPH Fellow, Public Health Prevention.
Presentation Title Presenter(s) Centers for Disease Control and Prevention AIDS Turning the Tide Together.
Meredith Carr, JD J. Stan Lehman, MPH David W. Purcell, JD, PhD Division of HIV/AIDS Prevention Centers for Disease Control and Prevention July 25, 2012.
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Management of Chronic HCV Infection by PMDs Rod Rahimi Osler Journal Club
Edited by Morris Sherman MD BCh PhD FRCP(C) Associate Professor of Medicine University of Toronto Protease Inhibitors in Chronic Hepatitis C: An Update.
HEPATITIS C VIRUS REINFECTION IN PEOPLE WHO INJECT DRUG (PWID) PREVIOUSLY SUCCESFULY TREATED G. Ntetskas, V. Papastergiou, L. Skorda, A. Katsili, E. Anastasiou,
Sexually Transmitted Disease Surveillance 2012 Division of STD Prevention.
Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.
Introduction to Tuberculosis Genotyping National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination.
OVERVIEW OF PROJECT INSPIRE NYC Marie Bresnahan, MPH Project Director May 20,
Public Health Response to Traumatic Brain Injury
Infection Prevention in US Outpatient Oncology Settings Alice Guh, MD. MPH National Center for Emerging and Zoonotic Infectious Diseases Division of Healthcare.
STDs in Persons Entering Corrections Facilities Sexually Transmitted Disease Surveillance 2009 Division of STD Prevention.
Poxvirus and Rabies Branch November 2011 Rabies Surveillance in the United States During 2010 Division of High-Consequence Pathogens and Pathology National.
Sexually Transmitted Disease Surveillance 2012 Division of STD Prevention.
HEPATITIS C Kimberly Klatt. CHARACTERISTICS  Virus  Enveloped  Single-stranded RNA virus  High mutation rate  6 different genotypes  Most cases.
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Sexually Transmitted Disease Prevention.
Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.
Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.
Hadziyannis SJ et al. EASL Peginterferon alfa-2a (40KD) (PEGASYS ® ) in combination with ribavirin (RBV): efficacy and safety results from a phase.
R2. 임형석 / Pf. 김병호. I NTRODUCTION Chronic hepatitis C infection 130~150 million worldwide 7 genotypes genotype 1 predominates(about 70% in USA): most difficult.
Template ID: junglegreens Size: 36x48 Impact of Hepatitis C Screening in Outpatient Population Madhuri Chandnani MD, Pallavi Pothuri MD, Michael Stevens.
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
Treatment of HBV/HCV Coinfection
Emily Weston, MPH 2016 Annual CSTE Meeting
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Abstract MOAB0301 Hepatitis C Care Cascade for People Living With HIV in the Country of Georgia Nikoloz Chkhartishvili1, A. Abutidze1, N. Bolokadze1, O.
Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.
Diagnostics in hepatitis C: The end of response-guided therapy?
Effectiveness of Sofosbuvir in terms of sustained virological response at 12 weeks after treatment (SVR12) BETWEEN treatment naïve AND treatment.
3rd International HIV/Viral Hepatitis Co-Infection Meeting HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access Sunday, 17 July.
Interactive Workshop.
Phase 3 Treatment-Naïve and Treatment-Experienced
HCV & liver transplantation
Cascade of care for persons newly diagnosed
Eradication of HCV induced by DAAs
Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.
Alcohol, Other Drugs, and Health: Current Evidence March–April 2017
Talking to Patients About HCV Treatment
Chronic Hepatitis C Virus Infection
Treating Hep C with Novel Agents
Figure 1 Patients cured of HCV infection
Jepkoech Kottutt1, Emilia D. Rivadeneira2, Susan Hrapcak2
Sandy Jones, Public Health Advisor
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.
ARV-trial.com IMPACT Study: SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease Design Open label ≥ 18 years Chronic HCV infection Genotype.
Diagnostics in hepatitis C: The end of response-guided therapy?
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Just when you thought you knew everything.
Presented by: Jeanette Shabazz, PhD, NP-C
A Guideline-Based Approach to HCV Care
Phase 3 Treatment-Naïve and Treatment-Experienced
Lesson 3: The HCV Care Continuum
بسم الله الرحمن الرحيم.
Pei-Yuan Su,Yu-Chun Hsu,Shun-Sheng Wu,Wei-Wen Su,Maw-Soan Soon
Hepatitis C case-finding – An opportunity for community pharmacy
Managing Hepatitis C in Vermont
Presentation transcript:

Division of Viral Hepatitis, CDC Performance of Algorithms Using Serial Hepatitis C RNA Tests to Predict Treatment and Cure Among Patients Infected with Chronic Hepatitis C Ademola Osinubi, MS Division of Viral Hepatitis, CDC MAY 19, 2018

Background ~3 million with chronic hepatitis C virus (HCV) infection HCV is a leading cause of liver related deaths Liver cirrhosis Liver cancer End stage liver disease Chronic HCV infection is curable Interferon-based therapy (1991-2013) –> 50% cure rates Direct Acting Antivirals (2013-present) – > 90% cure rates Highly effective across all HCV genotypes Minimal adverse effects High cost of treatment is a barrier to access Allison.2015.J Hepatol

Electronic Medical Record (EMR) EMR has been used to monitor HCV patients from diagnosis to cure, but required manual chart review We created a HCV registry from EMR data abstraction to assess HCV treatment and cure rates * Friedman.2013.Am J Pub Health

Grady Health System Grady Memorial Hospital is public safety net hospital for the city of Atlanta and the largest hospital in the state of Georgia

Objectives Using HCV RNA test results to assess the sensitivity and positive predictive value for various algorithms to determine: Treatment initiation with direct acting antivirals Cure measured by sustained virologic response

Methods: Data source HCV-related treatment information included: Patient-level data was extracted from Grady’s EMR Data used to create HCV registry of HCV-infected patients HCV-related laboratory data included: Anti-HCV antibody results HCV RNA test results Genotype test results HCV antiviral treatment regimens HCV-related treatment information included: Direct acting antiviral regimen Date of treatment initiation/completion

Analytic methods Included patients with HCV RNA test date or treatment start date after 1 Dec 2013 Developed 5 algorithms as a proxy: Treatment with direct acting antivirals (DAA) Cure measured by sustained virologic response (SVR) Calculated sensitivity and positive predictive value for each algorithm

Sensitivity and Positive Predictive Value Definitions treated/cured not treated/cured algorithm true Sensitivity=a/a + c PPV = a/a + b false Gold standards to compare serial HCV RNA algorithms Treatment: DAA regimen with start date or completion date SVR (cure): HCV RNA undetectable >24 weeks after treatment start date or >12 weeks after treatment completion date True positives a False positives b False negatives c True negatives d

Treatment Path for a Typical Patient with Chronic HCV-infection Receiving Care at Grady Time 4 weeks 12 weeks 24 weeks 36 weeks HCV RNA+ RX START RVR RX ENDS SVR 24 SVR 12 1ST HCVRNA TESTING 2ND HCV RNA TESTING 3RD HCV RNA TESTING 4TH HCVRNA TESTING 5TH HCV RNA TESTING The registry was designed to capture five most recent HCV RNA test results in order to capture all these HCV RNA testing events * Rx: Prescription; RVR: Rapid Virologic Response; SVR: sustained virologic resonse=cure

Algorithms as a proxy to determine Treatment

Any one of these 4 results reported Treatment Algorithm 1 An initial detectable HCV RNA test result followed by one sequential HCV RNA test result Time 4 weeks 12 weeks 24 weeks 36 weeks HCV RNA+ RX START RVR RX ENDS SVR 24 SVR 12 1ST HCV RNA TESTING 2ND HCV RNA TESTING 3RD HCV RNA TESTING 4TH HCVRNA TESTING 5TH HCV RNA TESTING HCV RNA + * Rx: Prescription; RVR: Rapid Virologic Response; SVR: sustained virologic resonse=cure Any one of these 4 results reported

Results: Treatment Algorithm 1 (N=1807) outcome treated not treated Sens % PPV % 1 Yes 667 475 96 58 No 31 634 2 Y 644 278 92 70 N 54 831 3 608 154 87 80 90 955 4 596 134 85 82 102 975 5 515 50 74 91 183 1059 Total treated with DAA in HCV registry by gold standard: 698

Any one of these test results is 10-fold less Treatment Algorithm 2 An initial detectable HCV RNA test result followed by one sequential HCV RNA test result that indicated at least 10–fold decrease in viral load compared to the initial test Time 4 weeks 12 weeks 24 weeks 36 weeks HCV RNA+ RX START RVR RX ENDS SVR 24 SVR 12 1ST HCVRNA TESTING 2ND HCV RNA TESTING 3RD HCV RNA TESTING 4TH HCVRNA TESTING 5TH HCV RNA TESTING HCV RNA+ * Rx: Prescription; RVR: Rapid Virologic Response; SVR: sustained virologic resonse=cure Any one of these test results is 10-fold less

Results: Treatment Algorithm 2 (N=1807) outcome treated not treated Sens % PPV % 1 Y 667 475 96 58 N 31 634 2 Yes 644 278 92 70 No 54 831 3 608 154 87 80 90 955 4 596 134 85 82 102 975 5 515 50 74 91 183 1059 Total treated with DAA in HCV registry by gold standard: 698

Any two of these test results reported Treatment Algorithm 3 An initial detectable HCV RNA test result followed by two sequential HCV RNA test results Time 4 weeks 12 weeks 24 weeks 36 weeks HCV RNA+ RX START RVR RX ENDS SVR 24 SVR 12 1ST HCVRNA TESTING 2ND HCV RNA TESTING 3RD HCV RNA TESTING 4TH HCVRNA TESTING 5TH HCV RNA TESTING HCV RNA+ * Rx: Prescription; RVR: Rapid Virologic Response; SVR: sustained virologic resonse=cure Any two of these test results reported

Results: Treatment Algorithm 3 (N=1807) outcome treated not treated Sens % PPV % 1 Y 667 475 96 58 N 31 634 2 644 278 92 70 54 831 3 Yes 608 154 87 80 No 90 955 4 596 134 85 82 102 975 5 515 50 74 91 183 1059 Total treated with DAA in HCV registry by gold standard: 698

Any two of these test results > 6 weeks apart Treatment Algorithm 4 An initial detectable HCV RNA test result followed by two sequential HCV RNA test results > 6 weeks apart from each other Time 4 weeks 12 weeks 24 weeks 36 weeks HCV RNA+ RX START RVR RX ENDS SVR 24 SVR 12 1ST HCVRNA TESTING 2ND HCV RNA TESTING 3RD HCV RNA TESTING 4TH HCVRNA TESTING 5TH HCV RNA TESTING Treatment Algorithm 4 An initial detectable HCV RNA test result followed by two sequential HCV RNA test results > 6 weeks apart from each other HCV RNA + * Rx: Prescription; RVR: Rapid Virologic Response; SVR: sustained virologic resonse=cure Any two of these test results > 6 weeks apart

Results: Treatment Algorithm 4 (N=1807) treated not treated Sens % PPV % 1 Y 667 475 96 58 N 31 634 2 644 278 92 70 54 831 3 608 154 87 80 90 955 4 Yes 596 134 85 82 No 102 975 5 515 50 74 91 183 1059 Total treated with DAA in HCV registry by gold standard: 698

Any three of these test result reported Treatment Algorithm 5 An initial detectable HCV RNA test result followed by three sequential HCV RNA test results Time 4 weeks 12 weeks 24 weeks 36 weeks HCV RNA+ RX START RVR RX ENDS SVR 24 SVR 12 1ST HCVRNA TESTING 2ND HCV RNA TESTING 3RD HCV RNA TESTING 4TH HCVRNA TESTING 5TH HCV RNA TESTING HCV RNA + * Rx: Prescription; RVR: Rapid Virologic Response; SVR: sustained virologic resonse=cure Any three of these test result reported

Results: Treatment Algorithm 5 (N=1807) outcome treated not treated Sens % PPV % 1 Y 667 475 96 58 N 31 634 2 644 278 92 70 54 831 3 608 154 87 80 90 955 4 596 134 85 82 102 975 5 Yes 515 50 74 91 No 183 1059 Total treated with DAA in HCV registry by gold standard: 698

Algorithms as a proxy to determine cure

One of these two test results Undetectable SVR Algorithm 1 An Undetectable HCV RNA test result ≥ 6 months (24 weeks) after the first detectable HCV RNA test result Time 4 weeks 12 weeks 24 weeks 36 weeks HCV RNA+ RX START RVR RX ENDS SVR 24 SVR 12 1ST HCVRNA TESTING 2ND HCV RNA TESTING 3RD HCV RNA TESTING 4TH HCV RNA TESTING 5TH HCVRNA TESTING One of these two test results Undetectable * Rx: Prescription; RVR: Rapid Virologic Response; SVR: sustained virologic resonse=cure Detectable

Results: SVR Algorithm 1 (N=442) outcome cured not cured Sens % PPV % 1 Yes 261 46 83 85 No 53 82 2 Y 249 23 79 92 N 65 105 3 4 247 19 93 67 109 5 Total Cured in the HCV registry by gold standard :314

One of these two test results Undetectable SVR Algorithm 2 Treated initiation algorithm 1 and an undetectable HCV RNA test result ≥ 12 weeks after the last HCV RNA test result Time 4 weeks 12 weeks 24 weeks 36 weeks HCV RNA+ RX START RVR RX ENDS SVR 24 SVR 12 1ST HCVRNA TESTING 2ND HCV RNA TESTING 3RD HCV RNA TESTING 4TH HCV RNA TESTING 5TH HCV RNA TESTING One of these two test results Undetectable * Rx: Prescription; RVR: Rapid Virologic Response; SVR: sustained virologic resonse=cure HCV RNA test reported

Results: SVR Algorithm 2 (N=442) outcome cured not cured Sens % PPV % 1 Y 261 46 83 85 N 53 82 2 Yes 249 23 79 92 No 65 105 3 4 247 19 93 67 109 5 Total Cured in the HCV registry by gold standard :314

One of these two test results Undetectable SVR Algorithm 3 Treated initiation algorithm 2 and an undetectable HCV RNA test result ≥12 weeks after the last HCV RNA test result Time 4 weeks 12 weeks 24 weeks 36 weeks HCV RNA+ RX START RVR RX ENDS SVR 12 SVR 24 1ST HCVRNA TESTING 2ND HCV RNA TESTING 3RD HCV RNA TESTING 4TH HCV RNA TESTING 5TH HCV RNA TESTING * Rx: Prescription; RVR: Rapid Virologic Response; SVR: sustained virologic resonse=cure One of these two test results Undetectable HCV RNA test reported

Results: SVR Algorithm 3 (N=442) outcome cured not cured Sens % PPV % 1 Y 261 46 83 85 N 53 82 2 249 23 79 92 65 105 3 Yes No 4 247 19 93 67 109 5 Total Cured in the HCV registry by gold standard :314

One of these two test results Undetectable SVR Algorithm 4 Treated initiation algorithm 3 and an undetectable HCV RNA test result ≥ 12 weeks after the last HCV RNA test result Time 4 weeks 12 weeks 24 weeks 36 weeks HCV RNA+ RX START RVR RX ENDS SVR 24 SVR 12 1ST HCVRNA TESTING 2ND HCV RNA TESTING 3RD HCV RNA TESTING 4TH HCV RNA TESTING 5TH HCV RNA TESTING One of these two test results Undetectable * Rx: Prescription; RVR: Rapid Virologic Response; SVR: sustained virologic resonse=cure HCV RNA test reported

Results: SVR Algorithm 4 (N=442) outcome cured not cured Sens % PPV % 1 Y 261 46 83 85 N 53 82 2 249 23 79 92 65 105 3 4 Yes 247 19 93 No 67 109 5 Total Cured in the HCV registry by gold standard :314

One of these two test results Undetectable SVR Algorithm 5 Treated initiation algorithm 4 and an undetectable HCV RNA test result ≥ 12 weeks after the last HCV RNA test result Time 4 weeks 12 weeks 24 weeks 36 weeks HCV RNA+ RX START RVR RX ENDS SVR 12 SVR 24 1ST HCVRNA TESTING 2ND HCV RNA TESTING 3RD HCV RNA TESTING 4TH HCV RNA TESTING 5TH HCV RNA TESTING One of these two test results Undetectable * Rx: Prescription; RVR: Rapid Virologic Response; SVR: sustained virologic resonse=cure HCV RNA test reported

Results: SVR Algorithm 5 (N=442) outcome cured not cured Sens % PPV % 1 Y 261 46 83 85 N 53 82 2 249 23 79 92 65 105 3 4 247 19 93 67 109 5 Yes No Total Cured in the HCV registry by gold standard :314

Summary of Key Results for Treatment Algorithm Sensitivities ranged from 74-96% and PPV ranged from 58-91% Algorithms 3 and 4 had the best combination of sensitivity (87% and 85% respectively) and PPV (80% and 82% respectively) Likely because it follows a typical patient treatment path: sequential HCV RNA measurements after a detectable HCV RNA indicating that a patient is being monitored

Summary of Key Results for SVR algorithm Sensitivities ranged from 79–83% and PPV ranged from 85–93% Algorithms all had similar performance A high PPV (92-93%) was found for each SVR algorithm based on the presence of undetectable HCV RNA test result 12 weeks after the last HCV RNA test result regardless which treatment algorithm was applied to the SVR algorithm

Limitations Missing treatment starts and end dates on a subset of patients HCV registry abstracted only up to five HCV RNA test results May have misclassify patients with > 12 weeks regimen May not be generalizable because limited to one health system Algorithms were not validated on external cohort

Conclusions & Recommendations Algorithms relying Serial HCV RNA tests can be used as a proxy for determining DAA treatment initiation and achievement of SVR on longitudinal data from an HCV registry where treatment data are unavailable Algorithms have the potential to be a powerful tool in monitoring trends in HCV treatment and cure in large data sets when treatment information is unavailable, though additional validation is needed

Acknowledgement Special Thanks to : Alexander J Millman, MDa Aaron M. Harris, MD, MPHa Claudia Vellozzi, MD, MPHa Lesley Miller, MDb Jennifer Lom, MDb a. Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta ,GA USA b. Emory University School of Medicine, Department of medicine, Division of General Medicine and Geriatrics, Atlanta, GA

Thank you! For more information please contact Centers for Disease Control and Prevention 1600 Clifton Road NE, Atlanta, GA 30333 Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348 E-mail: cdcinfo@cdc.gov Web: http://www.cdc.gov The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Office of the Director Place Office Title Here